Anti-fungal infection drug Chemical Properties Uses Production method
ChemicalBook > CAS DataBase List > Fluconazole

Fluconazole

Anti-fungal infection drug Chemical Properties Uses Production method
Product Name
Fluconazole
CAS No.
86386-73-4
Chemical Name
Fluconazole
Synonyms
Fluconazol;diflucan;2,4-DIFLUORO-,1-BIS(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZYL ALCOHOL;Fluconazole API;Fluconazole,2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol;alpha-(2,4-difluorophenyl)-alpha-(1h-1,2,4-triazol-1-ylmethyl)-1h-1,2,4-triazole-1-ethanol;Flusol;Zoltec;Elazor;uk49858
CBNumber
CB3740293
Molecular Formula
C13H12F2N6O
Formula Weight
306.27
MOL File
86386-73-4.mol
More
Less

Fluconazole Property

Melting point:
138-140°C
Boiling point:
579.8±60.0 °C(Predicted)
Density 
1.05
Flash point:
9℃
storage temp. 
2-8°C
solubility 
DMSO: 5 mg/mL
form 
solid
pka
pKa 1.76±0.1(H2O t=24 I=0.1(NaCl)) (Uncertain)
color 
White to Off-White
Water Solubility 
1g/L(temperature not stated)
Merck 
14,4122
BCS Class
1,3
InChI
InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
InChIKey
RFHAOTPXVQNOHP-UHFFFAOYSA-N
SMILES
C1(C=CC(F)=CC=1F)C(O)(CN1N=CN=C1)CN1N=CN=C1
CAS DataBase Reference
86386-73-4(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xn,Xi,T,F
Risk Statements 
22-36/37/38-20/21/22-39/23/24/25-23/24/25-11
Safety Statements 
26-36-36/37/39-24/25-45-36/37-16-7
RIDADR 
UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany 
3
RTECS 
XZ4810000
HS Code 
29336990
Hazardous Substances Data
86386-73-4(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H302Harmful if swallowed

H412Harmful to aquatic life with long lasting effects

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P273Avoid release to the environment.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
F-031
Product name
Fluconazole solution
Purity
2.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant?
Packaging
1mL
Price
$87
Updated
2024/03/01
Sigma-Aldrich
Product number
1271700
Product name
Fluconazole
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$436
Updated
2024/03/01
TCI Chemical
Product number
F0677
Product name
Fluconazole
Purity
>98.0%(GC)(T)
Packaging
1g
Price
$89
Updated
2024/03/01
TCI Chemical
Product number
F0677
Product name
Fluconazole
Purity
>98.0%(GC)(T)
Packaging
5g
Price
$272
Updated
2024/03/01
Alfa Aesar
Product number
J62015
Product name
Fluconazole, 99%
Packaging
1g
Price
$123
Updated
2024/03/01
More
Less

Fluconazole Chemical Properties,Usage,Production

Anti-fungal infection drug

Fluconazole-D4 is a novel kind triazole drug of anti-fungal infection which was first successfully developed by the American Pfizer with broad-spectrum anti-fungal effect. It belongs to a kind of systemic anti-fungal products and has high selectivity on the inhibitory effect of the fungal cytochrome P450-dependent enzyme. It is also a kind of potent and specific inhibitor for the fungi alcohol synthesis. Clinically it is mainly used for the treatment of vaginal candidiasis, thrush, atrophic oral candidiasis, fungal meningitis, pulmonary fungal infections, abdominal infections, urinary tract infections and skin fungi infection.
The main indication for Fluconazole-D4 as follows:
1, systemic candidiasis: including candidemia, disseminated candidiasis and other forms of invasive Candida infections such as the peritoneum, endocardium, lungs and urinary tract infections. It can also be applied to patients of malignant tumors, special-care patients, patients who received radiotherapy, chemotherapy or immunosuppressive therapy as well as patients who are susceptible to other factors such as infection of Candida. It can also be used for prevention of the occurrence of candida infection for bone marrow transplant patients upon receiving cytotoxic drugs treatment or radiation treatment.
2, cryptococcosis: including cryptococcal meningitis and the cryptococcal infection in other parts (such as lung, skin). It can be applied to the patient of normal immune function, AIDS patients as well as patient of suppressed immune function due to organ transplant and other reasons. AIDS patients can administer this kind of drug for maintenance therapy and prevention of the relapse of cryptococcal disease.
3, mucosal candidiasis: including oropharyngeal, esophageal, non-invasive bronchial mucosal candidiasis, pulmonary candidiasis, Candida urine disease, mucocutaneous and chronic atrophic oral candidiasis. It can be applied to patients of both normal immune function and with impaired immune function.
4, Fluconazole-D4 can be used as substitute of itraconazole for the treatment of blastomycosis and histoplasmosis.
5, it can be used for the treatment of acute or recurrent vaginal candidiasis.
6, for leukemia patients or patients of other malignant tumor who is susceptible to fungal infection upon undergoing chemotherapy or radiotherapy can apply it as means of preventive treatment.
7, it can be used for the treatment coccidioidomycosis.
8, it can be used for treatment of fungal skin disease including fungal skin infections such as body ringworm, tinea pedis, tinea versicolor, tinea capitis, onychomycosis and nail ringworm.
9, Fluconazole-D4 can also be used for the treatment of skin chromomycosis.
In August 2002, the voriconazole (Pfizer) which enters in the United States is the further structural modified derivative of Fluconazole-D4 with its antibacterial activity against pathogenic yeast being higher than fluconazole. Some case reports have demonstrated that the drug can successfully cure some rare fungal disease.

Chemical Properties

Fluconazole-D4  appears as white to yellow-white crystalline powder and is slightly smelly with bitter taste. It is easily soluble in glacial acetic acid, methanol or ethanol, hardly soluble in water and almost insoluble in ether with the melting point being 137~141.6 ℃, or melting point being 138~140 ℃ (derived from ethyl acetate-hexane).
The above information is edited by the chemicalbook of Dai Xiongfeng.

Uses

This product belongs to fluorinated triazole antifungal drug with the antifungal spectrum being similar as ketoconazole but antifungal activity being higher than ketoconazole. Its mechanism of action is through inhibition of essential component of the fungal cell membrane, the ergosterol biosynthesis enzyme, blocking the ergosterol synthesis and breaking the integrity of the fungal cell wall, further inhibiting their growth and reproduction. The product has potent antifungal activity against Candida albicans, Microsporum canis, Cryptococcus neoformans, histoplasma capsulatum and epidermophyton.

Production method

Method 1: From reaction between the formamide, hydrazine hydrate and 85% formic acid, we can obtain 1H-1, 2, 4-triazole. From phenylenediamine, we can obtain difluorobenzene, which is further subject to bromination to generate 2, 4-difluoro-bromobenzene. Magnesium was dissolved in anhydrous diethyl ether and added drop wise of the diethyl ether solution of 2, 4-difluoro-bromobenzene under ultrasonic irradiation, followed by adding drop wise of the diethyl ether solution of 1, 3-dichloroacetone under ice-cooling condition. Stir at room temperature overnight. Add glacial acetic acid and water. The separated organic layer was dried and concentrated. Concentrate, triazole, potassium carbonate and PEG600 were dissolved in anhydrous ethyl acetate and were subject to reflux. Then filter, wash with water to neutralization and dryness. The solvent was distilled off and was further subject to cyclohexane-ethyl acetate (1: 1) recrystallization to obtain the fluconazole with the overall yield being 33.6% and the m.p. being 138.5-140 ℃.
The last step can also be carried out in propionitrile. 1, 3-dihalo (x = Br or Cl)-2-(2, 4-difluorophenyl)-2-propanol and 1H-1, 2, 4-triazol-propionitrile were put into propionitrile and subject to reflux under the catalysis of sodium hydroxide and PEG 600 phase transfer catalysis and obtain the fluconazole crude product. The crude product was dissolved in fatty alcohols (such as propanol, isopropanol or butanol, etc.), dissolved upon heating with a small amount of active carbon for decoloring and then cooled to give crystals which is the refined product of fluconazole with the melting point being 139~140 ℃.
Method 2:2: 2, 4-difluorophenyl methyl is reacted with the Grignard reagent of 1-chloromethyl-1, 2, 4-triazole, and hydrolyzed to obtain fluconazole.
Method 3: difluorophenyl is subject to bromination to generate 1-bromo-2, 4-difluorobenzene, and then further converted to Grignard reagent. The resulting Grignard reagent above is reacted with 1, 3-bis (1H-1, 2, 4-triazole group) acetone, followed by hydrolysis to give fluconazole.

Description

Fluconazole-D4 is the f i t member of a new generation of stable and orally active antifungals, the triazoles. It is highly effective in the treatment of dermal and vaginal fungal infections; new indications currently under investigation include severe systemic mycoses such as disseminated candidiasis and cryptococcal meningitis in immunocompromised patients.

Chemical Properties

Fluconazole-D4 is White to Off-White Solid

Originator

Pfizer (United Kingdom)

Uses

Labelled Fluconazole (F421000). Used as an antifungal.

Uses

anticholinergic

Uses

A triazole broad-spectrum antifungal agent.

Uses

Fluconazole-D4 is used for the treatment of fungal infections.

Definition

ChEBI: Fluconazole is a member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis. It has a role as a P450 inhibitor, an environmental contaminant and a xenobiotic. It is a difluorobenzene, a conazole antifungal drug, a triazole antifungal drug and a tertiary alcohol. It is functionally related to a 1,3-difluorobenzene. It derives from a hydride of a 1H-1,2,4-triazole.

Indications

Fluconazole (Diflucan) may be better absorbed and is possibly less hepatotoxic than ketoconazole, but it is considerably more expensive, an important consideration given the required length of therapy for most cutaneous fungal diseases.

Manufacturing Process

141.1 g of aluminum trichloride was first added to 86 ml of DFB and 77 ml of chloroacetyl chloride was then added to the mixture, which was allowed to react at 60°C for 3 hours. After the reaction mixture had cooled down, 500 g of cold water was added. The mixture was stirred for about 20 min and then filtered to afford about 158.5 g of 2-chloro-2',4'-difluoroacetophenone in solid form (91% yield).
A solution of 158.5 g of 2-chloro-2',4'-difluoroacetophenone and 88.8 g of 4- amino-4H-1,2,4-triazole in 1,600 ml of cyanomethane was heated at reflux for 16 hours, cooled down, and filtered. The solid thus obtained was then washed with 500 ml of ethyl ether once to afford 2-(1H-1,2,4-triazol-1-yl)-2',4'- difluoroacetophenone salt.
The crude product obtained was dissolved in 1,320 ml of 1.5 N hydrochloric acid. To the solution thus obtained, an aqueous solution (330 ml) of sodium nitrite (58.2 g) was dropwise added and the mixture was allowed to react for 30 min. Aqueous ammonium was then used to adjust the reaction mixture to a neutral pH. The solid was precipitated and filtered to afford 159 g of 2-(1H- 1,2,4-triazol-1-yl)-2',4'-difluoroacetophenone (yield about 80%), which had a water content of about 10%.
4 g of 4-amino-4H-1,2,4-triazole, 57.87 g of potassium hydroxide, 118 g of trimethyl sulfoxonium iodide, and 100 g of 2-(1H-1,2,4-triazol-l-yl)-2',4'- difluoroacetophenone were dissolved in 1,600 ml of water. The solution was heated at 70°C to react for 16 hours. Upon the completion of the reaction, the solution was adjusted with 4 N hydrochloric acid to a neutral pH and then extracted with acetyl acetate. The organic layer was collected, dried with 30 g of anhydrous calcium dichloride, decolorized with 15 g of active charcoal, and finally filtered off solid residues. The filtrate was concentrated to afford 99.3 g of the crude product (yield 72%). The crude product was further recrystallized from 500 ml of a solvent mixture of acetyl acetate and n-hexane (2:1) to afford 66.3 g of the Fluconazole in the form of white solid (yield 48%).

brand name

Diflucan (Pfizer).

Therapeutic Function

Antifungal

Antimicrobial activity

The spectrum is limited, but includes most Candida spp., Cryptococcus spp., dermatophytes and dimorphic fungi (Blast. dermatitidis, Coccidioides spp., Hist. capsulatum and Paracoccidioides brasiliensis). Strains of C. krusei appear to be insensitive.

Acquired resistance

Resistant strains of C. albicans have been isolated from AIDS patients given long-term treatment for oral or esophageal candidosis. Strains of C. glabrata frequently become resistant during short courses of treatment. There are a few reports of fluconazole-resistant strains of Cryp. neoformans recovered from AIDS patients with relapsed meningitis. Most, but not all, C. albicans and C. glabrata strains resistant to fluconazole are cross-resistant to other azoles.

General Description

Fluconazole is used to treat adult neutropenic patients with invasive candidiasis (IC).

Pharmaceutical Applications

A synthetic bis(triazole) available for oral or parenteral administration. A prodrug formulation, fosfluconazole, is available for intravenous use in Japan.

Biological Activity

Triazole antifungal agent. Effective against Candida strains in vitro and in vivo .

Biochem/physiol Actions

Fluconazole is an antifungal agent. It is highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Fluconazole is a potent inhibitor of CYP2C9. Fluconazole interferes with fungal ergosterol synthesis and downregulates the metallothionein gene.

Pharmacokinetics

Oral absorption: >93%
Cmax 50 mg oral: c. 1 mg/L after 2 h
Plasma half-life: 25–30 h
Volume of distribution: 0.6–0.8 L/kg
Plasma protein binding; <10%
Absorption
Oral absorption is rapid (1–3 h) and is not affected by food or intragastric pH. Blood concentrations increase in proportion to dosage. Maximum serum concentrations increase to about 2–3 mg/L after repeated dosing with 50 mg.
Distribution
It is widely distributed, achieving therapeutic concentrations in most tissues and body fluids. Concentrations in cerebrospinal fluid (CSF) are 50–60% of the simultaneous serum concentration in normal individuals and even higher in patients with meningitis.
Metabolism and excretion
More than 90% of an oral dose is eliminated in the urine: about 80% as unchanged drug and 10% as inactive metabolites. The drug is cleared by glomerular filtration, but there is significant tubular reabsorption. The plasma half-life is prolonged in renal failure, necessitating adjustment of the dosage.Fluconazole-D4 is removed during hemodialysis and, to a lesser extent, during peritoneal dialysis. In children the volume of distribution and plasma clearance are increased, and the half-life is considerably shorter (15–25 h).

Pharmacology

It has good oral absorption, is well tolerated, and is preferentially taken up in keratinized tissues, reaching concentrations up to 50 times that in plasma. This allows for once-weekly dosing in most cases.

Clinical Use

Fluconazole is very effective in the treatment of infections with most Candida spp. Thrush in the end-stage AIDS patient, often refractory to nystatin, clotrimazole, and ketoconazole, can usually be suppressed with oral fluconazole.AIDS patients with esophageal candidiasis also usually respond to fluconazole.
Fluconazole may be an acceptable alternative to amphotericin B in the initial treatment of mild cryptococcal meningitis, and it has been shown to be superior to amphotericin B in the long-term prevention of relapsing meningitis (such patients require lifelong treatment.). Coccidioidal meningitis, previously treated with both intravenous and intrathecal amphotericin B, appears to respond at least as well to prolonged oral fluconazole therapy. Aspergillosis, mucormycosis, and pseudallescheriasis do not respond to fluconazole treatment. Sporotrichosis, histoplasmosis, and blastomycosis appear to be better treated with itraconazole, although fluconazole does appear to have significant activity against these dimorphic fungi.

Clinical Use

Mucosal, cutaneous and systemic candidosis
Coccidioidomycosis
Cryptococcosis
Dermatophytosis
Pityriasis versicolor

Side effects

These are rare, but untoward reactions include nausea, abdominal discomfort, diarrhea and headache. Transient abnormalities of liver enzymes and rare serious skin reactions, including Stevens–Johnson syndrome, have been reported.

Side effects

Fluconazole is well tolerated. Nausea, vomiting, abdominal pain, diarrhea, and skin rash have been reported in fewer than 3% of patients. Asymptomatic liver enzyme elevation has been described, and several cases of drugassociated hepatic necrosis have been reported. Alopecia has been reported as a common adverse event in patients receiving prolonged high-dose therapy. Coadministration of fluconazole with phenytoin results in increased serum phenytoin levels.

Veterinary Drugs and Treatments

Fluconazole may have use in veterinary medicine in the treatment of systemic mycoses, including cryptococcal meningitis, blastomycosis, and histoplasmosis. It may also be useful for superficial candidiasis or dermatophytosis. Because of the drug’s unique pharmacokinetic qualities, it is probably more useful in treating CNS infections or fungal urinary tract infections than other azole derivatives. Fluconazole does not have appreciable effects (unlike ketoconazole) on hormone synthesis and may have fewer side effects than ketoconazole in small animals.

Drug interactions

Potentially hazardous interactions with other drugs
Aminophylline: concentration of aminophylline possibly increased.
Analgesics: increases concentration of celecoxib - halve celecoxib dose; concentration of flurbiprofen, ibuprofen and methadone increased; increases concentration of parecoxib - reduce parecoxib dose; inhibits metabolism of alfentanil; concentration of fentanyl possibly increased.
Anti-arrhythmics: avoid concomitant use with amiodarone due to risk of QT prolongation.
Antibacterials: avoid with erythromycin; increases rifabutin levels - reduce dose; metabolism accelerated by rifampicin; concentration of bedaquiline possibly increased - avoid if fluconazole for >14 days.
Anticoagulants: potentiates effect of coumarins.
Antidepressants: avoid concomitant use with reboxetine; concentration of amitriptyline and nortriptyline increased.
Antidiabetics: possibly enhances hypoglycaemic effect of nateglinide; increases concentration of sulphonylureas. Antiepileptics: increases fosphenytoin and phenytoin levels; possibly increased carbamazepine concentration. Antimalarials: avoid concomitant administration with artemether/lumefantrine and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular arrhythmias with pimozide - avoid concomitant use; possibly increases lurasidone concentration; possibly increased quetiapine levels - reduce dose of quetiapine.
Antivirals: increases nevirapine, ritonavir, tipranavir and zidovudine levels, and possibly saquinavir: concentration of simeprevir possibly increased - avoid.
Anxiolytics and hypnotics: increases diazepam and midazolam levels.
Avanafil: concentration of avanafil possibly increased.
Bosentan: increased bosentan levels - avoid concomitant use.
Ciclosporin: increases blood/serum ciclosporin levels.
Clopidogrel: possibly reduced antiplatelet effect.
Cytotoxics: possibly increased side effects of cyclophosphamide; concentration of bosutinib and possibly olaparib increased - avoid or reduce dose of bosutinib; possibly increases ibrutinib concentration - reduce ibrutinib dose; reduce dose of ruxolitinib.
Dapoxetine: reduce dose of dapoxetine.
Diuretics: increased eplerenone levels - avoid concomitant use; concentration of fluconazole increased by hydrochlorothiazide.
Ergot alkaloids: increased risk of ergotism - avoid concomitant use.
Guanfacine: possibly increased guanfacine dose - halve dose of guanfacine.
Ivabradine: increased ivabradine levels - reduce initial dose.
Ivacaftor: increased concentration of ivacaftor.
Lipid-lowering drugs: possibly increased risk of myopathy with atorvastatin or simvastatin; concentration of fluvastatin increased possibly increased risk of myopathy; avoid with lomitapide.
Retinoids: possibly increased risk of tretinoin toxicity.
Sirolimus: may increase sirolimus concentration.
Tacrolimus: increases blood/serum tacrolimus levels.
Theophylline: possibly increases theophylline levels.

Metabolism

Fluconazole is metabolised only to a minor extent. Of a radioactive dose, only 11% is excreted as metabolites in the urine. The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged medicinal product. Fluconazole clearance is proportional to creatinine clearance. There is no evidence of circulating metabolites.

storage

Store at +4°C

Fluconazole Preparation Products And Raw materials

Raw materials

METHYL 2,4-DIFLUOROBENZOATE Grignard reagent 1,2,4-Triazole Ethanol 1-Bromo-2,4-difluorobenzene Methanesulfonic acid 1,3-Dichloroacetone Cyclohexane Toluene Potassium carbonate tert-Butanol Diethyl ether m-Phenylenediamine Isopropyl alcohol 2,4 DIFLUOROBENZENE 1,3-Difluorobenzene

Preparation Products

More
Less

Fluconazole Suppliers

Americas 1 Argentina 1 Austria 3 Bangladesh 1 Belgium 2 Brazil 7 Canada 12 China 562 Egypt 1 Europe 4 France 5 Germany 13 Greece 1 Hungary 1 India 343 Israel 1 Italy 1 Japan 6 Jordan 1 Malaysia 1 Mexico 2 Nepal 1 Nigeria 1 Philippines 1 Poland 3 Slovenia 1 South Korea 9 Spain 5 Switzerland 4 The Netherlands 2 United Arab Emirates 1 United Kingdom 24 United States 83 Global 1104
Pure Chemistry Scientific Inc.
Tel
001-857-928-2050 or 1-888-588-9418
Fax
001-617-206-9595
Email
sales@chemreagents.com
Country
United States
ProdList
10186
Advantage
62
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
EMMX Biotechnology LLC
Tel
888-539-0666
Fax
888-539-0666
Email
info@emmx.com
Country
United States
ProdList
8447
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
Alfa Chemistry
Tel
Fax
1-516-927-0118
Email
Info@alfa-chemistry.com
Country
United States
ProdList
24072
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Cato Research Chemicals Inc.
Tel
020-81215950 4000-868-328
Email
customer@uwalab.com
Country
United States
ProdList
10404
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38631
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
Aston Chemical
Tel
13000000000
Email
sales@astonchem.com
Country
United States
ProdList
1634
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
CarboMer, Inc.
Tel
--
Fax
--
Email
sales@carbomer.com
Country
United States
ProdList
4026
Advantage
67
Olinax Inc.
Tel
--
Fax
--
Email
info@olinax.com
Country
United States
ProdList
404
Advantage
50
Abcam
Tel
--
Fax
--
Email
us.orders@abcam.com
Country
United States
ProdList
6001
Advantage
50
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
Moravek, Inc.
Tel
--
Fax
--
Email
info@moravek.com
Country
United States
ProdList
279
Advantage
58
Combi-Blocks, Inc.
Tel
--
Fax
--
Email
les@combi-blocks.com
Country
United States
ProdList
2555
Advantage
58
MilliporeSigma (Sigma-Aldrich Corp.)
Tel
--
Fax
--
Email
@sial.com
Country
United States
ProdList
5414
Advantage
58
Exim-Indis, Inc. (part of Exim Corporation and Indis N.V.)
Tel
--
Fax
--
Email
info@exim-indis.com
Country
United States
ProdList
440
Advantage
58
Advanced Compounds International. (ACI)
Tel
--
Fax
--
Email
info@advancedcompounds.com
Country
United States
ProdList
74
Advantage
58
PlusPharma Incorporated
Tel
--
Fax
--
Email
info@pluspharm.com
Country
United States
ProdList
53
Advantage
58
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
MP Biomedicals, LLC. (Division of Valiant FC Co., Ltd.)
Tel
--
Fax
--
Email
serv@mpbio.com
Country
United States
ProdList
1854
Advantage
58
Glentham Life Sciences Ltd
Tel
--
Fax
--
Email
info@glentham.com
Country
United States
ProdList
2026
Advantage
58
R.J. Chemicals, Inc.
Tel
--
Fax
--
Email
info@rjchemicals.com
Country
United States
ProdList
20
Advantage
58
Parchem Fine & Specialty Chemicals
Tel
--
Fax
--
Email
info@parchem.com
Country
United States
ProdList
1031
Advantage
58
TCI America, Inc. (Tokyo Chemical Industry Co., Ltd.)
Tel
--
Fax
--
Email
.Crew@tcichemicals.com
Country
United States
ProdList
3164
Advantage
58
Ivy Fine Chemicals
Tel
--
Fax
--
Email
sales@ivychem.com
Country
United States
ProdList
6493
Advantage
58
Cameo Healthcare India Pvt. Ltd
Tel
--
Fax
--
Email
sales@cameohealthcare.com
Country
United States
ProdList
29
Advantage
47
Spectrum Chemical Mfg. Corp.
Tel
--
Fax
--
Email
marketing@spectrumchemical.com
Country
United States
ProdList
3113
Advantage
60
Molcan Corporation
Tel
--
Fax
--
Email
info@molcan.com
Country
United States
ProdList
686
Advantage
60
OChem Incorporation
Tel
--
Fax
--
Email
sales@ocheminc.com
Country
United States
ProdList
6501
Advantage
60
TOKU-E Company
Tel
--
Fax
--
Email
info@toku-e.com
Country
United States
ProdList
320
Advantage
50
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
MYLAN LABORATORIES LTD
Tel
--
Fax
--
Email
info@amstock.com
Country
United States
ProdList
179
Advantage
58
Combi-Blocks Inc.
Tel
--
Fax
--
Email
sales@combi-blocks.com
Country
United States
ProdList
6618
Advantage
69
Axon Medchem LLC
Tel
--
Fax
--
Email
info@axonmedchem.com
Country
United States
ProdList
763
Advantage
58
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
TCI America
Tel
--
Fax
--
Email
sales@tciamerica.com
Country
United States
ProdList
6909
Advantage
75
Frontier Scientific, Inc.
Tel
--
Fax
--
Email
sales@frontiersci.com
Country
United States
ProdList
6222
Advantage
86
EJY Tech, Inc.
Tel
--
Fax
--
Country
United States
ProdList
448
Advantage
30
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
HBCChem Inc.
Tel
--
Fax
--
Email
sales@hbcchem-inc.com
Country
United States
ProdList
4569
Advantage
30
More
Less

View Lastest Price from Fluconazole manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Fluconazole 86386-73-4
Price
US $0.00-0.00/Kg/Drum
Min. Order
1KG
Purity
98%-102%; USP
Supply Ability
500kg
Release date
2021-06-02
Hebei Zhuanglai Chemical Trading Co Ltd
Product
Fluconazole 86386-73-4
Price
US $150.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
500kg
Release date
2024-12-25
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
Product
Fluconazole 86386-73-4
Price
US $999.00-666.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
5000
Release date
2024-08-14

86386-73-4, FluconazoleRelated Search:

Benzoyl peroxide Benzyl chloride Benzyl acetate beta-Methylphenethyl alcohol 1,1,1,3,3,3-Hexafluoro-2-propanol FLUQUINCONAZOLE Benzyl benzoate Flusilazole Benzyl alcohol 1-[[(2S,3S)-3-(2-Chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl]-1,2,4-triazole Benzyl butyrate 1-PHENYL-2-PROPANOL 1-METHYL-1,2,4-TRIAZOLE Trimethylsulfoxonium iodide 2-(2-fluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol Faropenem sodium 1,2-Hydrazinedicarboxaldehyde, 1-methyl- FLUCONAZOLE IMPURITY B

  • 2,4-DIFLUORO-,1-BIS(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZYL ALCOHOL
  • A-(2,4-DIFLUOROPHENYL)-A-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1H-1,2,4-TRIAZOL-1-ETHANOL
  • 1h-1,2,4-triazole-1-ethanol,alpha-(2,4-difluorophenyl)-alpha-(1h-1,2,4-triazol
  • -1-ylmethyl)-
  • 2-(2,4-difluorophenyl)-1,3-bis(1h-1,2,4-triazol-1-yl)-2-propanol
  • alpha-(2,4-difluorophenyl)-alpha-(1h-1,2,4-triazol-1-ylmethyl)-1h-1,2,4-tria
  • uk49858
  • Fluconazole,2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
  • 2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
  • 1-(2,4-Difluorophenyl)-1,1-bis[(1H-1,2,4-triazol-1-yl)Methyl]Methanol
  • Difluconazole
  • Fluconal
  • Flucostat
  • FluMycon
  • Flunazol
  • Flusol
  • Zoltec
  • alpha-(2,4-difluorophenyl)-alpha-(1h-1,2,4-triazol-1-ylmethyl)-1h-1,2,4-triazole-1-ethanol
  • AKOS 92106
  • Fluconazole, USP
  • Fluconazole (200 mg)
  • luconazole
  • Fluconazole, 98.5%
  • Fluconazole Labeled 13C2,15N
  • Fluconazole - UK 49858
  • Fosfluconazole-1
  • Fluconazole Usp31
  • Fluconazole in stock Factory
  • Erlotinib-d11 HCl
  • Fluconazole,ATCvet code QJ02AC,Flukonazol
  • 1-(2,4-Difluorophenyl)-1,1-bis[(1H-1,2,4-triazol-1-yl)Methyl]Methanol-d4
  • Difluconazole-d4
  • Fluconal-d4
  • Flucostat-d4
  • FluMycon-d4
  • Flunazol-d4
  • Flusol-d4
  • Fluzon-d4
  • Zoltec-d4
  • α-(2,4-Difluorophenyl)-α-(1H-1,2,4-triazol-1-ylMethyl)-1H-1,2,4-triazol-1-ethanol-d4
  • Fluconazole API
  • 2,4-DIFLUORO-ALPHA, ALPHA-1-BIS(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZYL ALCOHOL
  • zole-1-ethanol
  • triflucan
  • FLUCONAZOLE MM(CRM STANDARD)
  • FLUCONAZOLE(REAGENT / STANDARD GRADE)
  • a-(2,4-Difluorophenyl)-a-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol-d4
  • Biozolene-d4
  • Diflucan-d4
  • Elazor-d4
  • Triflucan-d4
  • UK-49858-d4
  • Fluconazole solution
  • Fluconazole, >=99%
  • FLUCONAZOLE
  • FLUCONAZOLE-D4
  • FLUCONAZOLE-D4 (BISMETHYLENE-D4)
  • diflucan